Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer

Digestive Diseases and Sciences

Volumn 43, Issue 4, 1998, Pages 779-785

  Kovacs, Thomas O G ^a   Campbell, Donald ^b   Haber, Marian ^b   Rose, Pamela ^b   Jennings, Dennis E ^b   Richter, Joel ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Gastric ulcer; Lansoprazole; Maintenance therapy; Ulcer recurrence

Indexed keywords

LANSOPRAZOLE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STOMACH ULCER; ULCER HEALING; URTICARIA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; BIOPSY; CELL COUNT; DOUBLE-BLIND METHOD; ENTEROCHROMAFFIN-LIKE CELLS; FEMALE; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRINS; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMPS; RECURRENCE; STOMACH ULCER; TIME FACTORS;

EID: 0031946096     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018818115047     Document Type: Article

References (31)

1. Ihamaki T, Varis K, Siurela M: Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Scand J Gastroenterol 14:801-812, 1979
2. Kurata JH, Haile BM: Epidemiology of peptic ulcer disease. Clin Gastroenterol 13:289-305, 1984
3. Kurata JH, Nogowa AN, Abbey DE, Petersen F: A prospective study of risk for peptic ulcer disease in Seventh-Day Adventist. Gastroenterology 102:902-909, 1992
4. Bonnevie O: The incidence of duodenal ulcer in Copenhagen County. Scand J Gastroenterol 10:385-393, 1975
5. Bonnevie O: The incidence of gastric ulcer in Copenhagen County. Scand J Gastroenterol 10:231-239, 1975
6. School I-M, Mellstrom D, Oden A, Ytterberg B-O: Incidence of peptic ulcer disease in Gothenburg 1985. Br Med J 299:1131-1134, 1989
7. Jaszewski R, Calzada R, Dhar R: Persistence of gastric ulcers caused by plain aspirin or nonsteroidal antiinflammatory agents in patients treated with a combination of cimetidine, antacids, and enteric-coated aspirin. Dig Dis Sci 34:1361-1364, 1989
8. Collins AJ, Davies J, Dixon AS: A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis. Br J Rheumatol 27:106-109, 1988
9. Tytgat GNJ, Rauws EAJ: Campylobacter pylori and its role in peptic ulcer disease. Gastroenterol Clin North Am 19:183-196, 1990
10. Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt SD, Sisk C, Baskin WN, MacKercher PA, Hewett J: Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 91:517-520, 1979
11. 2-receptor antagonists for peptic ulcer disease. Aliment Pharmacol Ther 6:3-29, 1992
12. Soll AH: Gastric, duodenal, and stress ulcer. In Gastrointestinal Disease: Pathophysiology/Diagnosis/Management. M Sleisenger, J Fordtran (eds). Philadelphia, Saunders, 1993, pp 580-679
13. Taha AS, Hudson N, Hawkey CJ, et al: Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435-1439, 1996
14. Jensen DM, Cheng S, Kovacs TO, Randall G, Jensen ME, Reedy T: A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med 330:382-386, 1994
15. Holt S, Howden CW: Omeprazole: Overview and opinion. Dig Dis Sci 36:385-393, 1991
16. Nagaya H, Satoh H, Maki Y: Possible mechanisms for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells. J Pharmacol Exp Ther 252:1289-1295, 1989
17. Sachs G, Shin JM, Besancon M, Prinz C: The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 7(suppl 1):4-12, 29-31, 1993
18. Tolman KG, Sanders SW, Buchi KN: Gastric pH levels after 15 mg and 30 mg of lansoprazole and 20 mg omeprazole. Gastroenterology 106(suppl 4):A172, 1994
19. Müller P, Dammann HG, Leucht U, Simon B: Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 3:193-198, 1989
20. Takemoto T, Namiki M, Goto Y: Clinical evaluation of lansoprazole (AG-1749) for gastric ulcer: A multicenter double-blind comparison with famotidine. Rinsho Seijinbyo 21:327-345, 1991
21. Bardhan KD, Ahlberg J, Hislop WS, Lindholmer C, Long RG, Morgan AG, Sjostedt S, Smith PM, Stig R, Wormsley RG: Rapid healing of gastric ulcers with lansoprazole. Aliment Pharmacol Ther 8:215-220, 1994
22. Michel P, Lemaire M, Colin R, Bommelaer G, Rambaud JC, Dupas JL, Bigard MA, Vervaerd JC: Treatment of gastric ulcer with lansoprazole or ranitidine: A multicentre clinical trial. Aliment Pharmacol Ther 8:119-122, 1994
23. Florent C, Forestier M, Joubert-Collin M: Lansoprazole versus omeprazole: Efficacy and safety in acute gastric ulcer. Gastroenterology 104:A80, 1993
24. Tielemans Y, Hakanson R, Sundler F, Willems G: Proliferation of enterochromaffin-like cells in omeprazole-treated hypergastrinemic rats. Gastroenterology 96:723-729, 1989
25. Misawa T, Chijiiwa Y, Imazono Y: Effects of lansoprazole, a gastric proton pump inhibitor, on endocrine function and healing in patients with peptic ulcer. Ther Res 122:175-189, 1991
26. Ogoshi K, Kato T, Saito S: Clinical study of AG-1749 (lansoprazole): Effects on serum gastrin levels and gastric mucosal ECL cell density. Yakuri Chiryo 19:933-946, 1991
27. Larsson H, Carlsson E, Hakanson R, Mattsson H, Nilsson G, Seensalu R, Wallmark B, Sundler F: Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Gastroenterology 95:1477-1486, 1988
28. Brunner G, Arnold R, Hennig U, Fuchs W: An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. Aliment Pharmacol Ther 7(suppl 1):51-55, 1993
29. Solcia E, Bordi C, Creutzfeldt W, Dayal Y, Dayan AD, Falkmer S, Grimelius L, Havu N: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 41:185-200, 1988
30. Sharma B, Axelson M, Pounder RE, et al: Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1:67-76, 1987
31. Karnes WE, Berlin RG, Maxwell V, et al: Prolonged inhibition of acid secretion causes hypergastrinaemia without altering pH inhibition of gastrin release in humans. Aliment Pharmacol Ther 4:443-456, 1990